文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

基于最大偏差的溶出曲线可比性监管评估方法

Regulatory assessment of drug dissolution profiles comparability via maximum deviation.
PubMed 文献 · Stat Med · 2018-06-03

该研究提出一种基于曲线间最大偏差的推断框架,用于评估两种制剂溶出曲线的可比性,不依赖相似因子f2的适用性条件。模拟研究基于欧洲药品管理局三个真实案例,显示新方法在最大偏差大于10%相似接受限时控制I型错误率,小偏差时把握度超过80%。

要点

  • 新方法不依赖f2的适用性条件,可整合测量变异性。
  • 最大偏差大于10%相似接受限时控制I型错误率。
  • 小最大偏差时把握度超过80%,对抽样变异稳健。

核心结论

  • 基于最大偏差的推断框架可作为f2的有效替代方法,尤其当f2适用性条件不满足时。

研究设计与样本

  • 方法学研究,提出基于曲线间最大偏差的推断框架,并用欧洲药品管理局三个真实案例驱动的模拟研究进行基准测试。

主要发现

  • 模拟场景中,新方法在最大偏差大于10%相似接受限时控制I型错误率。
  • 小最大偏差时把握度超过80%,中间值更保守。
  • 结果对抽样变异非常稳健。

关键数值与推荐

  • f2超过50时判定溶出曲线相似,对应测试与参比制剂各时间点平均溶出百分比最大差异为10%。
  • f2的使用受《生物等效性研究指南》(CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **)中一组有效性条件限制。
  • 新方法在最大偏差大于10%相似接受限时控制I型错误率。

临床怎么用

  • 申请人可考虑将基于最大偏差的新方法作为f2的有效替代,尤其当f2有效性条件不满足时。

局限性

  • 原文未报告模拟研究的具体样本量、P值等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In drug development, comparability of dissolution profiles of 2 different formulations is usually assessed using the similarity factor f2 . In practice, the drug dissolution profiles are deemed similar if the f2 exceeds 50, which occurs when a 10% maximum difference in the mean percentage of the dissolved drug at each time point between test and reference formulation is obtained. According to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **) use of the f2 is however restricted by a set of validity conditions. If some of these conditions are not satisfied, the f2 is not considered suitable, and alternative statistical methods are needed. In this article, we propose an inferential framework based on the maximum deviation between curves to test the comparability of drug dissolution profiles. The new methodology is applicable regardless whether the validity criteria of the f2 are met or not. Contrary to the f2 , this approach also integrates the variability of the measurements over time and not only their average. To benchmark our method, we performed simulations informed by 3 real case studies provided by the European Medicines Agency and extracted from dossiers submitted to the Centralised Procedure for Marketing Authorisation Application. In the scenarios of the simulation study, the new method controlled its type I error rate when the maximum deviation was greater than the similarity acceptance limit of 10%. The power exceeded 80% for small values of the maximum deviation, while the test was more conservative for intermediate ones. Our results were also very robust to sampling variations. Based on these positive findings, we encourage applicants to consider the new maximum deviation-based method as a valid alternative to the f2 , especially when the validity criteria of the latter are not met.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Moellenhoff K, Dette H, Kotzagiorgis E, et al. Regulatory assessment of drug dissolution profiles comparability via maximum deviation. Stat Med. 2018. PMID: 29862526. doi:10.1002/sim.7689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。